Skip to main content
TipRanks
Go Ultimate75% OFF

Oryzon Genomics SA (0RDB) Share Price & Analysis

1 Followers

0RDB Stock Chart & Stats

€2.32-€0.01(-0.47%)
At close: 4:30 PM GMT
€2.4€2.6€2.8Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
EUR 2.24 - EUR 2.39
52-Week Range
EUR 2.24 - EUR 3.50
Previous Close
EUR 2.34
Volume
N/A
Average Volume (3M)
3,425
Market Cap
EUR 191.45M
Enterprise Value
EUR 230.85M
Total Cash (Recent Filing)
EUR 22.12M
Total Debt (Recent Filing)
EUR 7.10M
Price to Earnings (P/E)
―
Beta
0.43
Next Earnings
Mar 04, 2027 (Est.)
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Epigenetic Pipeline

A proprietary epigenetic drug platform gives Oryzon a focused foundation for developing differentiated therapies in areas of high unmet need. Advancing multiple applications across oncology and CNS disorders can broaden long-term opportunity if clinical programs successfully translate into medicines.

Supportive Balance Sheet

Low leverage and expanding assets and equity provide greater financial flexibility than the company’s early-stage profile might otherwise imply. This balance-sheet support can help Oryzon continue funding development programs and absorb operating volatility while limiting near-term dependence on heavy borrowing.

Strong Gross Profit In Revenue Years

Strong gross profit in periods when revenue was generated indicates that Oryzon’s underlying commercial or licensing activity can produce attractive direct economics. If revenue becomes more recurring, this gross-profit profile could support improved operating leverage as development spending is spread across a larger base.

Bears Say

Persistent Operating Losses

Sustained operating and net losses show that Oryzon has not yet converted its research platform into a profitable business. Continued losses can constrain internal reinvestment, increase reliance on external financing, and make long-term earnings power dependent on successful clinical and commercial progress.

Ongoing Cash Burn

Persistent negative operating and free cash flow means the business is not self-funding its research and development activities. Continued cash consumption can reduce financial flexibility over time and may require additional capital before the pipeline generates sustainable operating receipts.

Volatile Revenue Base

Repeated zero-revenue periods indicate that reported income is irregular rather than supported by a dependable recurring base. This volatility makes planning and forecasting more difficult, limits operating leverage, and leaves financial performance highly dependent on non-recurring or intermittent revenue sources.

Oryzon Genomics SA News

0RDB FAQ

What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest share price was €2.24 and its highest was €3.50 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is €191.45M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 107 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on Nov 10, 2026. The company reported -€0.018 earnings per share for the quarter, beating the consensus estimate of -€0.066 by €0.048.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Undervalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA pays a dividend of €0.285 which represents an annual dividend yield of ―. See more information on Oryzon Genomics SA dividends here
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -0.06.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 84,332,150 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of -€0.018 in its last earnings report, beating expectations of -€0.066. Following the earnings report the stock price went up 2.137%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in GB:0RDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology